Abeona Therapeutics Advances Commercial Rollout of Groundbreaking Gene Therapy

Abeona Therapeutics is progressing through key commercialization phases for its gene therapy ZEVASKYN, designed to treat recessive dystrophic epidermolysis bullosa (RDEB), commonly known as butterfly disease. With the first patient treated in December 2025, the company's focus is now shifting to scaling manufacturing and securing reimbursement from U.S. payers. Recent financial results and insider trading activity provide a mixed picture of the company's current trajectory.

The company's latest financial position was significantly influenced by a one-time event. For the first nine months of 2025, Abeona reported a net profit of $91.64 million. This result was primarily driven by the sale of a Priority Review Voucher (PRV) for $155 million in June 2025. Excluding this special item, the underlying operational performance tells a different story: the third quarter of 2025 saw a net loss of $5.2 million.

The regulatory backdrop for such vouchers remains favorable, as the relevant U.S. incentive program was extended until September 2029 earlier this week. Investors await more concrete data on the initial commercial performance of ZEVASKYN, which will be detailed in the next quarterly report scheduled for release between March 19 and 23, 2026. This update will be scrutinized for early revenue figures and their impact on operational losses.

Scaling Operations and Market Access

On the commercial front, the launch of ZEVASKYN is taking shape. Abeona has identified approximately 30 eligible patients within specialized treatment centers to date. To meet anticipated demand, the firm plans to increase its monthly manufacturing capacity from the current four to six slots to ten slots by mid-2026, with a further expansion envisioned by the end of 2027.

Should investors sell immediately? Or is it worth buying Abeona Therapeutics?

Concurrently, market access in the United States is improving. Major insurers, including United Healthcare, Cigna, and Aetna, have already provided coverage commitments. A critical milestone for streamlined reimbursement was the assignment of a permanent J-Code, effective January 1, 2026, which is expected to simplify billing processes for clinics administering the therapy. The company estimates that around 60% of potential U.S. patients are already covered under these insurance plans.

Pipeline Potential and Insider Activity

Additional future value drivers may emerge from Abeona's pipeline. Partner Ultragenyx resubmitted the Biologics License Application (BLA) for the gene therapy UX111 to the FDA in January. Abeona originally developed this program before transferring it. A regulatory decision from the agency is expected in the third quarter of 2026.

Recent securities filings show several company executives engaged in stock sales. On February 2, Director Christine Berni Silverstein sold 20,070 shares. Directors Donald A. Wuchterl and Eric Crombez also disposed of blocks of 14,814 and 16,284 shares, respectively.